Area of research
Hepatology · Molecular Biology
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Angiogenesis and VEGF in Cancer, Multiple Sclerosis Research Studies, and Gastric Cancer Management and Outcomes.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2).
Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer